Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 16/20 | 1.00 |
| ▸ | FAP | Q12884 | 14/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 1.00 |
| ▸ | DPP4 | P27487 | 9/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.50 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890341 | 0.86 | PREP (0.79) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL25890297 | 0.85 | PREP (0.77) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL25890370 | 0.83 | FAP (0.74) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL24067537 | 0.82 | PREP (0.70) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL17345171 | 0.82 | PREP (0.70) | PREPFAPDPP8DPP9 | |
| SCHEMBL17345293 | 0.81 | PREP (0.69) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL29162847 | 0.80 | PREP (0.67) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL29975671 | 0.80 | PREP (0.67) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL23876857 | 0.80 | PREP (0.67) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL23876868 | 0.78 | PREP (0.68) | PREPFAPDPP8DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| US-20250213681-A1 | NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION | OAKTREE FUND ADMINISTRATION, LLC | 2025-07-03 | — | — | US | disclosed |
| EP-3565560-B1 | PREDICTIVE AND DIAGNOSTIC METHODS FOR PROSTATE CANCER | ONKOSXCEL THERAPEUTICS LLC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240000928-A1 | APPROACH FOR TREATMENT OF CANCER VIA IMMUNOMODULATION BY USING TALABOSTAT | Jazz Pharmaceuticals, Inc. | 2024-01-04 | — | — | US | disclosed |
| US-20230227918-A1 | PREDICTIVE AND DIAGNOSTIC METHODS FOR PROSTATE CANCER | ONKOSXCEL THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| CN-116059218-A | Novel method for treating cancer using immunomodulation | 比奥克斯塞尔医疗股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059219-A | Novel method for treating cancer using immunomodulation | 比奥克斯塞尔医疗股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11613785-B2 | Predictive and diagnostic methods for prostate cancer | ONKOSXCEL THERAPEUTICS, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| US-11564986-B2 | Approach for treatment of cancer via immunomodulation by using talabostat | ONKOSXCEL THERAPEUTICS, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| CN-108136025-B | A novel method of treating cancer using immunomodulation | 比奥克斯塞尔医疗股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20220025061-A1 | COMBINATION THERAPIES FOR TREATING DISEASE USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST | OAKTREE FUND ADMINISTRATION, LLC | 2022-01-27 | — | — | US | disclosed |